We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+30.25%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12B
AUM Growth
+$2.23B
Cap. Flow
-$2.3B
Cap. Flow %
-19.15%
Top 10 Hldgs %
76.74%
Holding
140
New
18
Increased
23
Reduced
51
Closed
10

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$121M
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$106M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$76.4M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$34.6M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$653M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$73M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$30.8M
4
PCYC
PHARMACYCLICS INC
PCYC
+$17.3M
5
XOMA
Xoma
XOMA
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 40.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LPCN icon
76
Lipocine
LPCN
$17.1M
$3.38M 0.03%
28,775
-637
-2% -$69.3K
NDRM
77
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.35M 0.03%
250,000
– –
ASMB icon
78
Assembly Biosciences
ASMB
$498M
$3.31M 0.03%
+20,833
New +$2.82M
BLPH
79
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$3.21M 0.03%
+23,333
New +$3.63M
ABUS icon
80
Arbutus Biopharma
ABUS
$847M
$3.15M 0.03%
180,582
-303,574
-63% -$6.22M
ZGNX
81
DELISTED
Zogenix, Inc.
ZGNX
$3.15M 0.03%
287,308
-6,492
-2% -$73.5K
AUPH icon
82
Aurinia Pharmaceuticals
AUPH
$1.95B
$3.12M 0.03%
711,499
-16,170
-2% -$64.1K
IRWD icon
83
Ironwood Pharmaceuticals
IRWD
$586M
$2.71M 0.02%
201,981
-211,334
-51% -$2.77M
BDSI
84
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.69M 0.02%
255,866
+45,845
+22% +$626K
AFMD
85
DELISTED
Affimed
AFMD
$2.52M 0.02%
40,000
– –
ASPX
86
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$2.51M 0.02%
+25,000
New +$1.67M
ITCI
87
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.49M 0.02%
+104,166
New +$2.33M
ENTA icon
88
Enanta Pharmaceuticals
ENTA
$362M
$2.31M 0.02%
75,357
– –
SVRA icon
89
Savara
SVRA
$1.08B
$2.28M 0.02%
67,249
-957
-1% -$33.3K
VTAE
90
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$2.2M 0.02%
+187,597
New +$2.53M
ACHN
91
DELISTED
Achillion Pharmaceuticals
ACHN
$2.11M 0.02%
214,237
-224,100
-51% -$2.8M
PTN
92
Palatin Technologies
PTN
$14.4M
$2.09M 0.02%
1,640
– –
TCRT icon
93
Alaunos Therapeutics
TCRT
$4.64M
$2.04M 0.02%
1,262
-29
-2% -$43K
TARA icon
94
Protara Therapeutics
TARA
$214M
$2.01M 0.02%
4,323
– –
VXRT
95
DELISTED
Vaxart
VXRT
$1.99M 0.02%
78,471
-22,157
-22% -$610K
MRNS
96
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.8M 0.02%
50,000
-1,119
-2% -$49.1K
ASND icon
97
Ascendis Pharma A/S
ASND
$16.5B
$1.74M 0.01%
+100,000
New +$1.82M
CLLS
98
Cellectis
CLLS
$288M
$1.73M 0.01%
+50,000
New +$1.81M
ISEE
99
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.66M 0.01%
35,649
-1,127
-3% -$58.5K
MDWD icon
100
MediWound
MDWD
$184M
$1.63M 0.01%
32,143
– –
2 3
4
5 6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2015 Portfolio in Review

As of Q1 2015, Baker Bros. Advisors held 140 positions worth $12B, up 23% from $9.8B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors withdrew a net $2.3B in Q1 2015, closing 10 positions and reducing 51 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $653M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 42% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Invitae Corporation worth $110M.

  • Baker Bros. Advisors's largest Q1 2015 buy was Invitae Corporation: 6,554,967 shares worth $110M.
  • Baker Bros. Advisors added most to SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q1 2015, an estimated $106M increase.
  • Baker Bros. Advisors's biggest Q1 2015 reduction was Vanda Pharmaceuticals, cutting an estimated $30.8M.
  • Baker Bros. Advisors fully exited AVANIR PHARMACEUTICALS, INC CL A in Q1 2015, selling an estimated $653M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $12B portfolio in Q1 2015.
  • Baker Bros. Advisors opened 18 new positions and closed 10 in Q1 2015.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $12B.

Based on Baker Bros. Advisors's 13F filing for Q1 2015, filed 15 May 2015.